TNFRSF8 and granular cell tumor: We have previously shown that the CD30-directed antibody-toxin drug conjugate Brentuximab vedotin exhibits bystander cytotoxic activity following release of the uncoupled toxin after internalization of the antibody conjugate by successfully CD30-targeted GCT cells [48].